- Home
- HTGC vs DYN Comparison
HTGC vs DYN Comparison
Compare HTGC & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTGC | DYN |
|---|---|---|
| Founded | 2003 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.8B |
| IPO Year | 2005 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HTGC | DYN |
|---|---|---|
| Price | $16.60 | $16.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 17 |
| Target Price | $21.00 | ★ $39.94 |
| AVG Volume (30 Days) | 1.9M | ★ 2.0M |
| Earning Date | 02-12-2026 | 02-27-2026 |
| Dividend Yield | ★ 11.20% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | ★ $516,847,000.00 | N/A |
| Revenue This Year | $10.13 | N/A |
| Revenue Next Year | $9.62 | N/A |
| P/E Ratio | $9.58 | ★ N/A |
| Revenue Growth | ★ 4.54 | N/A |
| 52 Week Low | $15.65 | $6.36 |
| 52 Week High | $22.04 | $25.00 |
Technical Indicators
Market Signals| Indicator | HTGC | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 30.20 | 37.27 |
| Support Level | $16.22 | $16.10 |
| Resistance Level | $17.00 | $17.45 |
| Average True Range (ATR) | 0.38 | 1.02 |
| MACD | -0.16 | -0.11 |
| Stochastic Oscillator | 15.12 | 8.08 |
Price Performance
Historical ComparisonAbout HTGC Hercules Capital Inc.
Hercules Capital Inc is a specialty finance company that provides senior secured loans to high-growth, venture capital-backed companies in various technology, life sciences, and sustainable and renewable technology industries. It invests majorly in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The company lends to and invests in portfolio companies in various technology-related industries, including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.